Stevanato Group (STVN)
(Delayed Data from NYSE)
$19.87 USD
+1.08 (5.75%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $20.03 +0.16 (0.81%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth F Momentum D VGM
Brokerage Reports
Stevanato Group S.p.A. [STVN]
Reports for Purchase
Showing records 21 - 40 ( 62 total )
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Beats Estimates, but CAPEX Suggests Visibility into 2024-2026
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
JPM Takeaways, Positive Industry Backdrop for 2023
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Indiana on Horizon, Prefilled Syringe Data, Compelling FY23-25 Setup
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
3Q22 - Results Show Transition to Single Dose Syringe Era - CTLT, WST
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
3Q22: Positive Read for Tools Macro and WST/CTLT in Particular
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Management Meeting, Site Tour Italy, Accelerating Demand
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Life Sciences: COVID Era Concluding - Mapping Company Exposure
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Growth, Margins, COVID - Exceeded Metrics in 2Q
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
U.S. COVID-19 Vaccine Order Includes First-Time Single- Dose Format
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
2Q Preview - Mapping COVID Sales; 2023 Visibility Increasing
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Lots of Leading Indicators for Robust Pre-Filled Syringe Demand
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department